Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an ...
Q1 2026
Jun 1, 2026
Q3 2025
Nov 14, 2025
Q2 2025
Aug 14, 2025
Q1 2025
May 20, 2025
FY 2024
Feb 26, 2025